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Abstract
Background: Advanced glycation products (AGEs), as endogenous inflammatory mediator, compromise the
physiological function of mesenchymal stem cells (MSCs). MSCs have a potential role in cell replacement therapy in
acute myocardial infarction and ischemic cardiomyopathy. However, mechanisms of AGEs on MSCs are still not
unveiled.
Methods: Reactive oxygen species (ROS), genes regulation, cell proliferation and migration have been detected by
AGE-BSA stimulated MSCs.
Results: We found that in vitro stimulation with AGE-BSA induced generation of reactive oxygen species (ROS), and
inhibited dose-dependently proliferation and migration of MSCs. Microarray and molecular biological assessment
displayed an increased expression and secretion of Ccl2, Ccl3, Ccl4 and Il1b in a dose- and time-dependent
manner. These chemokines/cytokines of equivalent concentration to those in conditioned medium exerted an
inhibitory effect on MSC proliferation and migration after stimulation for 24 h. Transient elevation of phospho-p38
in MSCs upon AGE-BSA stimulation was blocked with p38 inhibitor.
Conclusions: The study indicates that AGE-BSA induces production of chemokines/cytokines in a dose- and time-
dependent manner via activation of ROS-p38 mediated pathway. These chemokines/cytokines exert an inhibitory
effect on MSC growth and migration, suggesting an amplified dysfunction of MSCs by AGEs.
Background
Emerging evidence has demonstrated that cell-based
therapy including mesenchymal stem cells (MSCs) for
acute myocardial infarction or ischemic cardiomyopathy
holds promise [1-3]. MSCs, isolated from bone marrow,
exhibit a high capacity of ex vivo expansion, allowing
further biological modifications and clinically huge-dose
preparation of the cells. Besides, MSCs are characterized
by great potential to transdifferentiate into cardiomyo-
cytes and vascular-like structure [4-6].
Diabetes is associated with adverse outcome after
myocardial infarction [7]. Not unexpectedly, the effects
of improving left ventricular function and reducing
infarct size after stem cell therapy, which are observed
in non-diabetes, have been significantly attenuated or
bleached in diabetic patients with acute myocardial
infarction [8]. Type 2 diabetes mellitus (T2DM) not
only decreases the abundance of bone marrow derived
CD133+ stem cells following acute myocardial infarc-
tion, but also limits their activation [9]. However, the
abnormal profiles of MSCs in diabetes and disease-
related mechanisms have been less clarified.
One of the reasons for stem cell dysfunction is due to
exposure of advanced glycation end products (AGEs) in
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are significantly associated with diabetic cardiovascular
complications and worse prognosis [10,11]. In vitro
stimulation with glyceraldehydes- or glycolaldehyde-
modified albumin reduces proliferation of MSCs, and
increases intracellular generation of reactive oxygen
species (ROS) and number of apoptotic cells, with
accompanying inhibition of adipogenic or chondrogenic
differentiation [12]. It remains unclear if glycated pro-
tein could amplify the inflammatory response in MSCs
and inhibit proliferation and migration of these cells.
The present study has shown that AGE-BSA dose-
dependently inhibited proliferation and migration of
MSCs via ROS-p38 MAPK-mediated pathway. Microarray
analysis and molecular biological approach of gene expres-
sions displayed increased expression and secretion of che-
mokines and cytokines including CC chemokine ligand
(Ccl) 2, Ccl3, Ccl4 and interleukin (Il)-1 beta. Notably,
these proinflammatory factors of equivalent concentration
to those in conditioned medium (AGE-BSA, 200 ug/ml)
functioned to inhibit proliferation and migration of MSCs.
Materials and methods
The Animal Care Committee of the National Cardiovas-
cular Center approved the experimental protocol.
Cell culture
Isolation and expansion of MSCs were performed as pre-
viously described [13]. Briefly, bone marrow cells were
isolated from male Sprague Dawley rats (weighing 100-
150 g) by flushing out the femoral and tibial cavities with
phosphate-buffered saline. Cells were grown in low glu-
cose Dulbecco’s Modified Eagle Medium, supplemented
with 10% fetal bovine serum, 100 U/ml penicillin and 100
ug/ml streptomycin (Gibco, NY, USA). These cells were
proved to be positive for CD29 (Biolegend, CA, USA)
and CD90 (eBioscience, CA, USA) surface markers and
negative for CD34 (Santa cruz, CA, USA) and CD45
(Abcam, Cambridge, UK) [14]. The STEMPRO osteogen-
esis and adipogenesis differentiation kits (Gibco) were
used to detect the capacity of MSC differentiation.
MTT assay
The proliferation of MSCs was tested by 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
( M T T ,S i g m a - A l d r i c h ,M o ,U S A )[ 1 5 ] .M S C s( 1×1 0
4/
well) were plated on a 96-well plate and stimulated by
different factors at varying doses and time points. OD
was measured by Microplate Reader (Bio-Rad, CA,
USA) at 490 nm (n = 3).
Measurement of intracellular ROS generation
Intracellular formation of ROS was evaluated using a
fluorescent probe CM-H2DCFDA (Invitrogen, CA, USA)
as previously described [16]. Briefly, cells were seeded in
a 6-well plate (2 × 10
5 cells/well), and incubated with 10
uM CM-H2DCFDA for 60 min at 37°C. Cell nucleus
was labeled by Hoechst 33342 (Sigma-Aldrich), and
images were then taken (Olympus, Tokyo, Japan). The
ROS fluorescence intensity was analyzed using Flow
cytometry (BD, NJ, USA) (n = 3).
Wound healing
Wound healing assay was performed as previously
described [17]. Briefly, MSCs were grown to confluence
in 60-mm
2 dishes and starved for 24 h. After comple-
tion of a linear wound, medium was changed to fresh
DMEM with or without addition of factors. At 0 and 24
h, images were taken (Olympus). The area of each dish
was measured using IMAGE-PRO PLUS Version 6.2
(Media Cybernetics, MD, USA).
Boyden chamber assay
Chemotaxis was measured using a 48-well Transwell
plate (Millipore, MA, USA). MSCs at 60-70% confluence
were starved overnight in serum-free DMEM, trypsi-
nized, and resuspended in serum-free DMEM (3 × 10
4
cells/300 ul). The cell suspension was added to the
upper chamber, and the bottom chamber was filled with
DMEM with 10% FBS or serum-free medium. The
chamber was incubated at 37°C in a CO2 incubator for
5 h, then the filter was removed and nonmigrated cells
were scraped from the upper surface. The migrated cells
were stained and treated with lysis buffer, and number
of cells was then quantified by OD 560 nm
measurement.
Microarray analysis of gene expression
MSCs (5 × 10
5)w e r ep l a t e do n6 - c md i s h e sa n dc u l -
tured with AGE-BSA (200 ug/ml) (Calbiochem, Darm-
stadt, Germany) for 12 and 24 h. Total RNA was
extracted from cells using an RNeasy Mini kit (Qiagen,
Hilden, Germany). Then, 10 ug of total RNA was
reverse-transcribed to produce biotin-labeled cRNA,
with GeneChip One-Cycle Target Labeling and Control
Reagents (Affymetrix, CA, USA). After fragmentation,
10 ug of cRNA was hybridized with GeneChip Rat Gen-
ome 230 2.0 Array. GeneChips were then scanned using
a GeneChip Scanner 3000. Normalization, filtering, and
gene ontology analysis were performed with GeneSpring
GX 7.3.1 software (Agilent Technologies, CA, USA).
The detected signals were assessed by gene hierarchi-
cal clustering of logarithmic values at each time point,
and then displayed in a heatmap. Clustering was per-
formed using Cluster 3.0 and the patterns were created
and viewed using Java TreeView 1.0.13 software. Raw
data from each array were analyzed using Mul-Class Dif
[18-20]. Gene coexpression networks based upon
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tions among genes [21]. Moreover, for assessing certain
properties of the networks, k-cores in graph theory was
introduced as a method of simplifying graph topology
analysis [22,23].
Quantitative real-time RT-PCR
Total RNA was extracted as described above. Briefly, 5
ug of total RNA was reverse-transcribed into cDNA
using a reverse transcription system (Promega, WI,
USA). PCR amplification was performed with Power
SYBR Green PCR Master Mix (Applied BioSystems, CA,
USA) in a StepOne (Applied BioSystems). The oligonu-
cleotides used in quantitative real-time RT-PCR analysis
are listed in Table 1. Gene expression levels were nor-
malized with beta-actin, and data were analyzed with
StepOne software v2.1 (Applied BioSystems).
Measurement of chemokines/cytokines in conditioned
medium
The supernatant of MSCs was collected after stimulatio-
nôand levels of Ccl2, Ccl3, Ccl4 and Il1b were measured
using commercially available ELISA kits of Ccl2, Il1b(all
for Invitrogen), Ccl3 (ABD Serotec, NC, USA) and Ccl4
(eBioscience).
Effect of chemokines/cytokines on MSCs
Since the distinct effects of Ccl2, Ccl3, Ccl4 and Il1b (all
for Invitrogen) on MSCs might be disturbed using con-
ditioned medium, MSCs were therefore stimulated by
commercially available chemokines/cytokines with
equivalent concentration at low and high doses (as phy-
siological or disease status [24-29]). Proliferation and
migration were evaluated by MTT and wound healing
assays.
Western blot
Cells were lysed with the ProteoJET Mammalian Cell
Lysis Reagent (Fermentas, MD, USA) to extract cytopla-
mic proteins. Equal amounts of protein extracts were
subjected to 12% SDS/PAGE and blotted onto a poly
(vinylidene difluoride) membrane. The membrane was
blocked and probed overnight at 4°C with antibodies
against total or phosphorylated p38 (Cell Signaling
Technology, MA, USA), followed by incubation with
horseradish peroxidase-conjugated secondary antibodies
for 1 h at room temperature. Blots were developed
using an ECL detection system (Millipore, MA, USA).
Each image was captured and the intensity of each band
was analyzed with Quantity One (Bio-Rad).
AGE-BSA stimulation and p38 inhibition
MSCs were seeded on 96- or 6-well culture plates for
MTT, microarray assay, ROS measurement, cytokine/
chemokine detection, RT-PCR or western blot analysis.
Cells were incubated with AGE-BSA (Calbiochem) at
varying concentrations and up to different time points.
To probe the effect of P38 inhibition on activation of
AGE-BSA stimulated cells, MSCs were pretreated with
SB203580 (20 uM) (Merck, Darmstadt, Germany) 1 h
before AGE-BSA stimulation. The concentration of inhi-
bitor used was based upon dose-response experiments
(data not shown), with the maximal inhibitory effect.
For each experiment, cell viability was always more than
90%. Cell-free supernatants were collected and stored at
-80°C until analysis.
Statistical analysis
All values are expressed as mean ± SD. Student’s paired
t test was performed for comparison of paired samples,
and ANOVA was used for multiple group comparisons,
followed by Friedman’s posttest. A probability (p) value
< 0.05 was considered significant.
Results
AGE-BSA induced ROS accumulation and attenuated
proliferation of MSCs
Fluorescence-activated cell sorting (FACS) showed that
MSCs were negative for CD34 and CD45, and strongly
expressed CD29 and CD90. When cultured in adipo-
genic or osteogenic medium, MSCs were differentiated
into adipocytes or osteoblasts (see Additional File 1; Fig-
ure S1). The MTT assay showed that AGE-BSA time-
and dose-dependently inhibited proliferation of MSCs,
with concentration of 200 ug/ml exhibiting remarkable
effects at 24 h (p < 0.05, Figure 1A). AGE-BSA regulated
RAGE expression (Figure 1B). After stimulation
with AGE-BSA (200 ug/ml) at 12 or 24 h, profuse ROS
generation was observed in MSCs (both p < 0.05)
(Figure 1C and Figure 1D).
Table 1 Primers used in real-time PCR
Gene Name Product size (bp) Sense primer Anti-sense primer
b-actin 176 CGTTGACATCCGTAAAGACC TAGAGCCACCAATCCACACA
Ccl2 280 AATGAGTCGGCTGGAGAA GCTTGAGGTGGTTGTGGA
Ccl3 155 GCTGCCCTTGCTGTTCTT CAAAGGCTGCTGGTCTCA
Ccl4 148 TCTCCTCCTGCTTGTGGC GCAAAGGCTGCTGGTCTC
Il1-b 190 GGATGGTGGAGCAAGGG GCACTGCTTCCCAGGCTT
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Wound healing assay revealed that AGE-BSA produced
a concentration-dependent decrease in migration of
MSCs (Figure 2A and 2B). Similarly, AGE-BSA at these
concentrations obviously inhibited transwell migration
(all p < 0.05) (Figure 2C and 2D).
Gene expression regulated by AGE-BSA
The genes with significant change (p < 0.05 and FDR <
0.05) were selected (Table 2). Cluster analysis was
shown in Figure 3A. Coexpression network of AGEs-
induced genes was built (Figure 3B), in which Ccl2,
Ccl3, Ccl4 and Il1b were located centrally.
Microarray assay revealed an elevated expression of
Ccl2, Ccl3, Ccl4 and Il1b after induction of AGEs.
Real-time PCR verified a time- and dose-dependent
increase of these chemokines/cytokines after incuba-
tion with AGE-BSA (Figure 3C and Figure 3D). As
expected, the levels of Ccl2, Ccl3, Ccl4 and Il1b
displayed a time- and dose- dependent increase (n = 3,
p < 0.01) (Figure 3E and 3F).
Activity of p38 pathway and chemokines/cytokines
MAP kinases including p38, ERK 1/2 and JNK showed
(see Additional File 2; Figure S2) that only p38 pathway
affected proliferation and migration of MSCs. Stimula-
tion with AGE-BSA (200 ug/ml) resulted in increased
phosphorylation of p38 at 20, 30 and 50 min (Figure 4A).
In contrast, blockage of p38 by SB203580 significantly
attenuated effects of AGE-BSA on proliferation, migra-
tion and chemokine/cytokine secretion of MSCs (Figure
4B, 4C and 4D). Notably, a time- and dose-dependent
inhibition of cell proliferation and migration were
induced by Ccl2, Ccl3, Ccl4 and Il1b (Figure 4E and 4F)
Discussion
The present study demonstrates that AGE-BSA inhibits
proliferation and migration of MSCs, and induces
Figure 1 Effects of AGE-BSA stimulation on MSC proliferation and ROS production. (A) MSCs were stimulated by AGE-BSA and BSA (as
negative control) for MTT testing (mean ± SD, n = 3). (B) AGE-BSA treated MSCs, and RAGE has been detected. (C) MSCs stimulated by AGE-BSA
for 12 and 24 h were labeled with CM-H2DCFDA. ROS fluorescence intensity was analyzed using flow cytometry (mean ± SD, n = 3; *P < 0.05,
**P < 0.01 vs. control). (D) MSCs were labeled with CM-H2DCFDA and Hoechst 33342. Images were taken with different fluorescence
wavelengths (200×).
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Page 4 of 10Figure 2 Effects of AGE-BSA stimulation on MSC migration. (A) MSCs stimulated by AGE-BSA and BSA (as negative control) for 24 h. Images
were taken (40×). (B) Velocity of MSC migration was measured in um/min. (C) MSCs stimulated by AGE-BSA and BSA for 24 h were labeled with
buffer of cell stain. Images were taken (200×). (D) Lyses were quantified by OD 560 nm measurement. (mean ± SD, n = 3; *P < 0.05, **P < 0.01
vs. un-stimulated cells).
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time-dependent manner via activation of ROS-p38
mediated pathway. Furthermore, these chemokines/cyto-
kines exert an inhibitory effect on MSCs growth and
migration, suggesting an amplified dysfunction of MSCs
by AGEs stimulation.
Interaction of AGEs and receptor for AGEs (RAGE)
relays cell surface signals to various intracellular path-
ways including p38, JNK/STAT and other mitogen-
activated protein kinases. Activation of p38 pathway is
responsible for a myriad of transcriptional programs
leading to enhance expression of pro-inflammatory cyto-
kines [24-26]. Over-production of intracellular ROS
results in inflammatory activation and impairment of
physiological function [27,28], and constitutes a key ele-
ment in diabetic pathophysiology. In this study, we
observed an increased ROS production and elevated p38
phosphorylation in MSCs by AGE-BSA stimulation,
accompanying with reduced proliferation and migration
and increased pro-inflammatory cytokine/chemokine
production in MSCs. The extent of MSC abnormalities
was closely related to the dose of AGEs, whereas block-
age of p38 reverses these pathological changes. Collec-
tively, our results suggest that AGEs cause abnormal
growth and migration of MSCs, and trigger production
of pro-inflammatory factors via generation of ROS and
activation of p38 pathway.
Recently study demonstrated that p38 pathway activa-
tion has been associated with interleukin-6 (IL-6),
cyclooxygenase-2 (COX-2) and CCL2 expression
increased in the heart. The long-term activation of p38
also regulated post-infarct cardiac remodeling in type 2
diabetes. Glucagon-like peptide-1 is an incretin hormone
that effects on glucose metabolism and may involve acti-
vation of p70s6 kinase, ERK1/2, and p38 MAPK. All of
these research indicated that p38 involved in coronary
heart disease [29-31].
In this study, a dose- and time-dependent over-expres-
sion of Ccl2, Ccl3, Ccl4 and Il1b in MSCs by AGE-BSA
stimulation was evident. Previous studies have demon-
strated that in vivo levels of these pro-inflammatory che-
mokines/cytokines are significantly associated with type
Table 2 Multi-class differentiation analysis of genes
Description Gene symbol p-value FDR
EGF-like module containing, mucin-like, hormone receptor-like 1 Emr1 7.00E-07 0.0003
Chemokine (C-C motif) ligand 3 Ccl3 1.00E-06 0.0003
Chemokine (C-C motif) ligand 2 Ccl2 1.04E-05 0.0022
Interleukin 1b Il1b 2.27E-05 0.0032
Chemokine (C-C motif) ligand 4 Ccl4 2.43E-05 0.0032
Transferrin receptor Tfrc 3.18E-05 0.0034
Integrin alpha L Itgal 0.0003331 0.0309
NAD(P)H dehydrogenase, quinone 1 Nqo1 0.000419 0.0340
Fatty acid binding protein 3, muscle and heart Fabp3 0.0004791 0.0341
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha Nfkbia 0.000525 0.0341
Transferrin receptor Tfrc 0.0007492 0.0442
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon Nfkbie 0.0010249 0.0512
Glutathione S-transferase A2 Gsta2 0.0010941 0.0512
Interferon induced transmembrane protein 1 Ifitm1 0.0011035 0.0512
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide Fcer1g 0.0015853 0.0686
Fc receptor-like S, scavenger receptor Fcrls 0.0027302 0.1107
Synaptic vesicle glycoprotein 2b Sv2b 0.003675 0.1403
Doublesex and mab-3 related transcription factor 2 Dmrt2 0.0078799 0.2841
Matrix metallopeptidase 12 Mmp12 0.0091006 0.3109
Stearoyl-Coenzyme A desaturase 1 Scd1 0.0101781 0.3303
Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) Runx1t1 0.0138214 0.4254
Allograft inflammatory factor 1 Aif1 0.0144188 0.4254
Rho GTPase activating protein 5 Arhgap5 0.0162094 0.4574
F-box protein 5 Fbxo5 0.0174488 0.4718
Zinc finger protein 367 Zfp367 0.0237975 0.6178
Origin recognition complex, subunit 6 like (yeast) Orc6l 0.0252814 0.6311
A kinase (PRKA) anchor protein 12 Akap12 0.0334329 0.7749
Family with sequence similarity 122B Fam122b 0.0361249 0.8085
Solute carrier family 6 (neurotransmitter transporter, taurine), member 6 Slc6a6 0.0465527 0.8886
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Page 6 of 10Figure 3 Gene expression regulated by AGE-BSA. (A) Ccl2, Ccl3, Ccl4 and Il1b showed significant difference (p < 0.01) in MSCs stimulated by
AGE-BSA for 12 and 24 h using Cluster 3.0 software. (B) k-core of gene expression was analyzed by GeneRelNet, and net of gene co-expression
was drawn. (C) Time- and (D) dose-dependent expression of chemokines/cytokines stimulated by AGE-BSA. b-actin was used to normalize the
results. (E) Time- and (F) dose-dependent chemokine/cytokine production stimulated by AGE-BSA (mean ± SD, n = 3; *P < 0.05, **P < 0.01 vs.
un-stimulated cells). (mean ± SD, n = 3; *P < 0.05, **P < 0.01 vs. un-stimulated cells).
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cal outcomes [32-40]. Consistent with previous findings,
our study further showed that chemokines/cytokines of
concentration equivalent to those in conditioned med-
ium exerted an inhibitory effect on MSC growth and
migration. Notably, the concentrations of these pro-
inflammatory factors in this experiment were also simi-
lar to in vivo levels in diabetic patients [[33,35,36] and
[39]]. Thus, autocrine-released chemokines/cytokines
from MSCs by AGEs stimulation and those from other
sources jointly contributed to impairment of cellular
function.
Based upon these observations, we hypothesized that
migrated or transplanted MSCs may be functionally dys-
regulated in diabetic, hypoxic and inflammatory
environment and exhibit low growth rate and impaired
function. Inflammation is intensified with significant
release of pro-inflammatory chemokines/cytokines from
MSCs. These factors, with diabetic milieu, in return
further damage cellular function, which mitigate the
therapeutic effects of MSCs in diabetes. Interestingly,
mildly elevated levels of Ccl2, Ccl3, Ccl4 and Il1b stimu-
lated MSC homing and promote repairing of the
damage tissues in non-diabetic physiological conditions
[41-46].
Conclusions
T h ep r e s e n ts t u d yd e m o n s t r a t e sa ni n h i b i t o r ye f f e c to f
AGEs on MSC proliferation and migration via ROS- p38-
mediated pathway and production of pro-inflammatory
Figure 4 Effects of AGE-BSA on MSCs via p38 pathway. (A) MSCs were incubated with AGE-BSA and p38 phosphorylation was assessed
(gray value). (B) Proliferation of MSCs stimulated by AGE-BSA and SB 203580 was determined by MTT. (C) Migration of MSCs stimulated by AGE-
BSA and SB 203580 was determined by wound healing assay. (D) Ccl2, Ccl3, Ccl4 and Il1b secretion of MSCs stimulated by AGE-BSA and SB
203580 was evaluated. (mean ± SD, n = 3; *P < 0.05, **P < 0.01 vs. AGE-BSA stimulated cells) (E) MSCs stimulated with different doses and times
of Ccl2, Ccl3, Ccl4 and Il1b were determined by MTT (mean ± SD, n = 3). (F) MSCs were stimulated by different doses of chemokines/cytokines,
and migration velocity was calculated by wound healing assay (um/min). (mean ± SD, n = 3; *P < 0.05, **P < 0.01 vs. cells stimulated with low
dose).
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trol and anti-inflammation should be emphasized espe-
cially in patients with diabetes undergoing cell therapy
with MSCs.
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Additional material
Additional File 1: Fig. S1 Characterization of isolated MSCs. (A)
STEMPRO Osteogenesis differentiation medium induced MSC
osteogenesis, stained by alkaline phosphatase. STEMPRO Adipogenesis
differentiation medium induced MSC adipogenesis, stained by oil red O.
The entire image was taken (10×). (B) Flow cytometry shows the passage
3 MSCs were negative for reactivity to antigens CD45 and CD34, and
positive for reactivity to antigens CD90 and CD29.
Additional File 2: Fig. S2 Effect of other MAPK pathway stimulated
by AGE-BSA. (A) ERK1/2 and JNK phosphorylation of MSCs incubated
with AGE-BSA (200 ug/ml for 0, 10, 20, 30, 40, 50 and 60 min) was
determined (gray value). (B) Proliferation of MSCs incubated with AGE-
BSA (200 ug/ml) and PD 98059 (20 uM) or JNK inhibitor Ⅱ (10 nM) for 0,
12 and 24 h was assessed by MTT. (C) Migration of MSCs incubated with
AGE-BSA (200 ug/ml) and PD 98059 (20 uM) or JNK inhibitor Ⅱ (10 nM)
for 24 h was determined by wound healing assay. (mean ± SD, n = 3; P
â 0.05 vs. AGE-BSA stimulated cells).
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